Global Digital Health 2025:

Re-Priced, Re-Proved, Re-Focused

Funding and Key Trends

Investment Trends • Pipeline Maturity

Category Focus • Proof Points

Therapeutic Focus • Noteworthy Deals

Partnerships • Alpha Forecaster • Implications



Powered by HealthTech Alpha – the AI-native system of record for Digital Health intelligence.

Published by Galen Growth.

10 YEARS | GALEN GROWTH

A Decade of Redefining Digital Health Intelligence

State of Digital Health: 2025 Retrospective

Re-priced. Re-proved. Re-focused.

2025 was the year digital health re-priced and re-proved itself.

After the post-2021 correction, capital did not return evenly; it concentrated into operational winners with demonstrable adoption, credible economics, and implementation capability. At the same time, buyers—particularly health systems—asserted sharper demands around workflow fit and measurable ROI, raising the threshold for what qualifies as “innovation” worth scaling. In this new market, evidence and distribution became the true differentiators: not the promise of impact, but the ability to prove it, deliver it inside real clinical and operational workflows, and scale it through credible channels. The result is a sector heading into a reopening Exits market where the winners are increasingly identifiable, and where the costs of being wrong, for investors and operators alike, are materially higher.

For investors, this matters because risk has shifted from technology feasibility to execution and adoption. Failure modes now include sales cycle drag, integration friction, weak retention, and evidence that does not map to purchasing criteria. Diligence should therefore focus on repeatable go to market, implementation burden, gross margin trajectory, retention and expansion, and the quality of evidence clinical, operational, and economic relative to the buyer’s decision process.

For corporates, the implication is that partnering and BD should move from broad scouting to fewer, deeper relationships anchored in distribution and proof: prioritise partners who can embed into provider workflows, generate measurable outcomes, and scale through established channels rather than one-off pilots.

For health systems, the shift creates leverage and responsibility: demand interoperability, measurable value tied to clinician time and patient outcomes, clear implementation ownership, and evidence that holds up in your environment—not in controlled demos.

For startups, the message is clear: to raise, sell, or go public, you must be able to demonstrate durable adoption, defendable distribution, and credible evidence at a level that satisfies procurement, compliance, and outcomes scrutiny—because “AI” and novelty no longer substitute for proof, workflow fit, and scalable commercial performance.



HEALTHTECH ALPHA

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2025 Key Takeaways: Concentration, Buyer Power & Proof

+9%

Venture Funding

Global digital health funding reached **$28.8 billion in 2025, up 9% from 2024**, as investors focused on ventures demonstrating **real-world impact, scalability, and credible exit strategies**. Europe led regional growth with a 15% year-on-year increase.

2.2x

Deal Size

The average global digital health **deal size in Q4 surged 2.2 times over Q4 2024,** reaching a five-year high of **$34.1 million per deal**. Notably, European late-stage deals saw their average deal size grow 4.1x over 2024, reflecting **increased investor confidence** and a focus on high-value opportunities.

18%

Health Systems

Providers are increasingly shaping digital health innovation, accounting for **18% of over 2,370 partnerships in 2025**, as health systems co-develop and integrate solutions to address **workforce shortages and rising demand.**

49%

Mega Deals

In 2025, mega deals valued at $100 million or more accounted for **49% of all digital health funding**, with 65 such deals totalling $14.0 billion. This concentration of large investments significantly drove up the average deal size across the sector.

-9%

Venture M&A

After a surge in mergers and acquisitions in 2024, digital health ventures shifted focus in 2025 from consolidation to capital formation, with **acquisition volume falling 9%** and returning to 2023 levels. **Fundraising took centre stage,** and public market activity showed early signs of life, suggesting that while M&A slowed, momentum may build again in 2026.

© 2026 by Galen Growth - All rights reserved.

Why This Matters: The 2026 Lens by Stakeholder

IMPLICATIONS

Investors		2026 will reward discipline over breadth: **concentrate on category leaders with provable adoption, margins, and evidence**; expect longer diligence cycles and fewer “story rounds”
Corporates		Partnering should shift from “innovation scouting” to measurable operating outcomes (time saved, cost reduced, adherence improved); **treat integration readiness and evidence plans as gating criteria.**
Health Systems		Procurement leverage is increasing—standardise venture requirements around interoperability, measurable ROI, and workflow fit; **de-prioritise pilots without a clear scale pathway**.
Ventures		The bar has moved: **design for integration, demonstrate impact fast, and build repeatable go-to-market economics**; “AI” is not differentiation unless it reduces workload and improves outcomes.

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Digital Health - Innovating Across the Entire Healthcare Value Chain



Digital Health is not just about patient-facing solutions like mobile apps or telemedicine platforms. **It's a revolutionary ecosystem of digital and technological innovations permeating every link of the healthcare value chain**. Digital Health is redefining how healthcare operates at every level, from drug discovery and development to clinical trials, supply chain optimisation, diagnostics, hospital management systems, insurance, and regulatory compliance.

By embracing this expansive view, we recognise that digital transformation impacts all facets of healthcare. Cutting-edge technologies such as artificial intelligence, machine learning, IoT, and blockchain optimise operational efficiency, enable personalised medicine, and foster collaboration among stakeholders—not just improve patient outcomes.

HealthTech Alpha's industry-standard taxonomy captures this comprehensive perspective, mapping Digital Health innovation across the entire healthcare value chain. This holistic approach allows stakeholders to uncover innovation opportunities beyond patient interfaces and appreciate the profound potential of digital health in data analytics, medical devices, pharmaceutical processes, and healthcare delivery infrastructure.

Digital Health—as structured within HealthTech Alpha—is a dynamic, all-encompassing ecosystem where innovation seamlessly integrates across the entire healthcare value chain, far exceeding the confines of patient solutions alone.

See slides 54 and 87 for further details on our taxonomy.

© 2026 by Galen Growth - All rights reserved.

What we counted (and what we did not)

Source of Data

Unless otherwise stated, all data are exclusively sourced from Galen Growth's proprietary database **HealthTech Alpha™** – the global leading Digital Healthcare Technology Innovation data, intelligence and insights platform. Presently, HealthTech Alpha tracks billions of data points and has a coverage exceeding 16,000 Digital Health ventures across the globe. For more information, visit https://www.healthtechalpha.com/

Data Scope

The 2025 year-end venture and partnerships analyses within the report consider ventures across the globe, with selected analysis focusing on six key regions for Digital Health: North America, Asia Pacific, the Middle East, western Europe, South America (key markets), and Africa.

The following scope of analysis criteria must be met to be included in this report:

- The venture was incorporated after 2002
- The venture has been qualified as being Digital Health, i.a.w. Galen Growth's rigorous taxonomy - see slide 54
- The venture's geographic location is determined by its initial country of incorporation
- Venture funding includes all stages up to but excluding the exit event
- Subsidiaries of large corporations (e.g. Microsoft) are excluded



Explore 16,000+ Ventures
In HealthTech Alpha

Methodology

Analytics presented in this report are Galen Growth's proprietary algorithms and are explained on slide 88.

© 2026 by Galen Growth - All rights reserved.

Trusted Insights: Independent, Data-Driven & Sector-Specialist

10 YEARS | GALEN GROWTH

A Decade of Redefining Digital Health Intelligence



Unmatched Expertise & Data-Driven Insights

High-quality, actionable research and insights for investors, corporates, and startups.

Powered by HealthTech Alpha

The leading intelligence platform for Digital Healthcare Technology

No Hype. No Bias. No Anecdotes

Purely data-driven insights, ensuring objective, evidence-backed analyses.

Digital Health Experts, Not Generalists

Led by industry veterans, not 30-something analysts with little sector expertise.

Over a Decade of Digital Health

A proven track record of unmatched industry data and thought leadership.

Independent & Agenda-Free

Our insights are driven by data and expertise, not sponsorships.

Make Informed Decisions

Gain the competitive edge with **Galen Growth's trusted, unparalleled research**.

© 2026 by Galen Growth - All rights reserved.



10 YEARS | GALEN GROWTH

A Decade of Redefining Digital Health Intelligence

Contents

2 Foreword & Key Takeaways

9 Hype to Hard Results

20 Exits & 2026 Outlook

29 Ecosystem Insights

37 Investment Insights

53 Cluster Focus

61 Therapeutic Focus

67 Regional Snapshots

- 69 United States
- 74 Europe
- 79 Asia Pacific

85 Reference Notes

Global 2025

Hype to Hard Results:

Repricing, Proof & Concentration

In 2025

$28.8B ▲+9% YoY

of total funding (excluding exits)

were deployed across

1335 Deals ▼-33% YoY

globally


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Europe Strengthened, the US Remains the Centre of Gravity

After years of bold promises, digital health in 2025 was all about **proving results**. The era of frenzy and hype gave way to a steadier, more evidence-driven approach. Funding levelled off to healthy, sustainable levels, and the industry focused on what works rather than on what merely sounds exciting. Europe continued its growth trajectory, **with funding rising 15% from 2024, making it the fastest-growing region**. North America maintained its leadership in total funding volume and continues to lead in venture capital deployed.

Global Venture Funding*	
2021	$60.6B
2022	$35.7B
2023	$24.4B
2024	$26.4B
2025	$28.8B



* Not including post-exit financing events

© 2026 by Galen Growth - All rights reserved.

Funding Implications: Decision-Making Changes for 2026

IMPLICATIONS

Investors		Lower deal velocity means fewer chances to correct—**prioritise resilient unit economics and credible paths to profitability; reserve more capital for follow-ons into winners.**
Corporates		Venture landscape will consolidate; **now is the window to secure strategic partnerships with fewer, stronger players and negotiate clearer outcome-based scopes.**
Health Systems		Expect fewer “new” ventures and more platform offerings; **focus on rationalising stacks and expanding proven solutions rather than expanding pilot portfolios.**
Ventures		Plan for a funding environment where raising is episodic: **extend runway, drive revenue earlier, and show efficient growth**; anticipate tougher pricing discussions with buyers.


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

US Capital Increasingly Underwrites Europe's Growth

In 2023, late-stage investments in European ventures were primarily led by European investors, who accounted for the majority of deals. By 2025, their participation has declined sharply, while the **number of US investors participating in investment rounds for European ventures has surged**, now accounting for 62% of all participants in late-stage European digital health deals, a threefold increase from 2023.

Distribution of Investors Participating in Late-Stage Deals for Digital Health Ventures in Europe, by Investor Headquarters Location




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

The Valuation Question: is Europe Pricing Ahead of Fundamentals?

The entry of US investors into the European digital health ecosystem has fuelled higher-value funding rounds, especially in Late-Stage rounds, where the **average deal size grew 4.1x**, driving rising venture valuations across the region. While this influx of capital has accelerated growth and visibility for European ventures, it also risks pushing valuations beyond levels the region has historically supported, particularly given Europe's longer go-to-market timelines and limited exit options.

Average Ticket Size for European-Founded Ventures ($M / Deal)



Notable Mega-Deals in Europe in 2025

	Venture	Funding	Category	Investors
ŌURA	Ōura	$900M	Wearbles	Fidelity, ICONIQ Partners, Whale Rock, Atreides Management
NEKO	Neko Health	$260M	Medical Diagnostics	Lightspeed Venture Partners, General Catalyst, OG Venture Partners, Rosello, Lakestar, Atomico
AMBOSS	Amboss	$259M	Medical Education	KIRKBI, M&G Investments, Lightrock and more.
Isomorphic Laboratories	Isomorphic Labs	$600M	Drug Discovery	Thrive Capital, GV, Alphabet
CMR SURGICAL	CMR Surgical	$200M	Prescriptive Analytics	Trinity Capital, Lightrock, SoftBank

© 2026 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Buyer Power: Providers Force Workflow & ROI Discipline


As health systems worldwide grapple with mounting pressures—ranging from workforce shortages and rising costs to increased patient demand—digital transformation has become not just an opportunity, but a necessity. In 2025, the urgent need for efficiency gains and operational resilience has propelled Health Management Solutions to the forefront of digital health investment, overtaking Research Solutions as the top-funded cluster.

Facing unprecedented challenges, health systems and hospitals are turning to digital tools that streamline clinical workflows, optimize resource allocation, and enhance patient care. This strategic pivot is reflected in partnership activity: in 2025, providers accounted for 18% of the more than 2,370 partnerships announced across the digital health ecosystem. These collaborations underscore a sector-wide recognition that technology-driven solutions are essential for navigating crises and building sustainable, future-ready healthcare systems.

2025 Top Funded Digital Health Clusters



2025 Venture Partnership Share by Industry Vertical



© 2026 by Galen Growth - All rights reserved.

Health System Implications

Investors		Prioritise workflow-adjacent categories (documentation, care navigation, revenue cycle, operations) where adoption is fastest; **diligence should include integration burden and change management risk.**
Corporates		Providers increasingly dictate what scales; **align partnerships to provider priorities** (capacity, throughput, clinical productivity) rather than only brand or engagement metrics.
Health Systems		You are the market-maker—**codify what "value" means internally (time saved per clinician, reduced length of stay, reduced admin burden) and require vendors to prove it**
Ventures		**Sell outcomes, not features;** quantify time saved, error reduction, and operational uplift; build implementation playbooks and champion-driven adoption models.

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Capital Deployment in 2025: Workflow, Reimbursement Fit & Evidence-Ready Models

Global venture funding remained positive in 2025, with capital flowing into clusters and therapeutic areas that address pressing healthcare needs and demonstrate strong growth potential. Oncology was the top-funded therapeutic area, although it saw an annual decline in funding (-12%), while Preventive Health (+104%) experienced a sharp increase, fuelled by Neko Health and Ōura. Health Management Solutions took the top spot in the digital health cluster, with funding increasing by 50% and overtaking Research Solutions.

Change in venture funding by Therapeutic Area



Change in venture funding by Digital Health Cluster

Top 5 **Digital Health Clusters**	**YoY Change, 2024 to 2025**
Health Management Solutions	50% ↑
Research Solutions	-19% ↓
Medical Diagnostics	-33% ↓
Telemedicine	55% ↑
Wellness	74% ↑

© 2026 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Capital Concentration: Mega-Deals Dominate Outcomes


In 2025, mega deals—valued at $100 million or more—remained a defining force in the digital health funding landscape across Europe and N. America. Their momentum signalled sustained investor appetite for high-value opportunities in standout companies, driven in part by expectations of a reopening IPO window and attractive near-term exit prospects.

In 2025, 65 mega deals were completed, totalling $14.0 billion and representing 49% of all digital health funding. North America remained the global leader in mega-deal activity, while Europe maintained the elevated deal volume it reached in 2024.

Historical Volume of Mega Deals



Regional Distribution of Mega Deals



© 2026 by Galen Growth - All rights reserved.

Mega Deals Implications

Investors		The market is polarising—returns will concentrate in a smaller set of scaled leaders; **apply a "category dominance" test and avoid mid-tier players without a clear edge.**
Corporates		When capital concentrates, counterparties gain negotiating leverage—**secure access early (commercial terms, exclusivity where appropriate) and focus on fewer, deeper partnerships.**
Health Systems		Large financing rounds signal venture staying power but do not guarantee implementation success; **require performance commitments, governance, and integration accountability regardless of size.**
Ventures		In a winner-takes-more market, differentiation must be structural (data advantage, distribution, integration footprint, evidence); **if you are not leading, consider partnerships, niches, or strategic consolidation paths.**

IMPLICATIONS

© 2026 by Galen Growth - All rights reserved.

Global 2025

Exits & 2026 Outlook:


Building Momentum for Growth to Face a Changing Market

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Consolidation Continued: Tuck-Ins & Capability Buys Continue

After a surge in M&A in 2024, venture activity in 2025 pivoted decisively from consolidation to capital formation. Acquisition volume fell 9% back to 2023 levels, while fundraising took centre stage. Public market activity showed early signs of life: IPOs ticked up, while SPACs remained largely dormant, with just a single completed transaction (Nanyang Biologics, Singapore). Looking ahead, momentum may build in 2026, as Freenome has announced a planned SPAC merger with Perceptive Capital Solutions Corp., targeting a NASDAQ listing under the ticker "FRNM," with closing expected in Spring 2026.

Volume of Investor Exits (IPO, M&A, SPAC)



Acquisition Share of Digital Health Ventures, by Industry Vertical and Year



© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Acquisitions: Who is Buying, and What They are Buying

Venture-to-venture acquisitions continue to dominate digital health M&A, a pattern expected to accelerate in 2026 as many growth- and late-stage ventures reloaded their balance sheets with fresh capital in 2025. At the same time, sustained financial pressure on younger ventures is expected to drive down acquisition prices, presenting attractive opportunities for established players to expand. In 2025, ten private ventures executed multiple acquisitions; among these, the most active acquirers—based on total deals over several years—are highlighted below.

Most active acquirers in 2025

Acquirer		Digital Health Category	# of 2025 Acquisitions	Total # of Acquisitions	2025 Acquired Ventures	Date	Category of Acquired Venture
datavant	Datavant	EHR/PHR	2	6	Aetion	5 / 2025	Prescriptive Analytics
					DigitalOwl	9 / 2025	Health Claim Mgmt
COACHCARE	CoachCare	Physician/Clinic	2	5	VitalTech	3 / 2025	Care Coordination
					MD Revolution	6 / 2025	Disease Management
innovaccer	Innovaccer	EHR / PHR	2	4	Humbi AI	1 / 2025	Hospital
					Story Health	9 / 2025	Care Coordination

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


DTP Expands – But Unit Economics & Regulation Define Success

Over the past year in the U.S., the pharma industry has made a decisive pivot from traditional direct-to-consumer (DTC) marketing toward full-fledged **direct-to-patient (DTP)** infrastructure. This shift reflects Big Pharma's strategic evolution from influencing patient demand to **orchestrating the entire patient journey,** from diagnosis through prescription, payment, and delivery.

Nearly all large pharmaceutical firms now operate or are developing DTP initiatives (94% according to recent analysis[1]) signalling that direct engagement with patients has become a **core strategic capability** rather than a marketing experiment. Major launches from **Eli Lilly (LillyDirect)**, **Pfizer (PfizerForAll)**, **Novo Nordisk (NovoCare Pharmacy)**, and **AstraZeneca (AstraZeneca Direct)** have defined the new model, with programs offering telehealth-based initiation, digital pharmacy fulfilment, and transparent cash-pay pricing for blockbuster therapies such as GLP-1s and migraine treatments.

While it captures significant focus, DTP remains concentrated in the U.S., where regulatory and reimbursement conditions enable direct patient engagement at scale. Even there, it is largely reserved for drugs with very large patient populations that justify dedicated platforms.

Timeline: Direct-to-Patient Platforms for Large Pharma



1. Galen Growth: TrumpRx Drug Price Mandate Disrupts Pharma's Direct-to-Patient (DTP) Evolution: 3 Key Hypotheses
2. Single-product DTP websites have not been shown, such as BMS Eliquis ® and Novartis Cosentyx ®

Read more about Big Pharma's strategic evolution and DTP evolution in Galen Growth's Pharmaceutical Innovation Index 2025 Report

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Policy Will Shape DTC in 2026: What Changes, What Stays



The Evolving Landscape and Regulatory Outlook

Despite strong momentum, DTP is still volatile. The forthcoming TrumpRx initiative—a federal price-aggregation platform—adds new pressure by commoditising cash-pay pricing and exposing the lowest-cost options, threatening manufacturers' pricing advantages.

DTP isn't reversing, but it is being stress-tested. As federal programs reshape pricing and access, manufacturers will need to rethink how they reach patients while preserving the economics that support future R&D.



Pharma's Role in Shaping the Future of Healthcare

The transition to patient-centric business models in the pharmaceutical industry, exemplified by LillyDirect, PfizerForAll, and Astellas DIGITIVA, underscores the critical role of digital health innovations in shaping the future of healthcare. Additionally, the potential for other major pharmaceutical companies to adopt similar strategies highlights the industry's commitment to enhancing patient care through technology.

By partnering with specialised digital health companies, these pharmaceutical leaders are not only enhancing accessibility and convenience but also driving better health outcomes through personalised, holistic care. As the digital health landscape evolves, the collaborative efforts between pharma and digital technologies innovators will be pivotal in creating more resilient, responsive, and patient-focused healthcare systems.


Explore more policy and pharmaceutical topics in Galen Growth's Blogs and Research Reports

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2026 Operating Conditions: Tailwinds and Headwinds

Ongoing regulatory changes, evolving payer policies, and rapid technological advancements continue to shape the direction of digital health. Ultimately, these ongoing shifts mean that digital health innovators must remain agile, as success will depend on their ability to adapt to a landscape where regulatory support and payer decisions can rapidly redefine both opportunities and risks.



© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

IPO Watchlist 2026: Who is Ready?

As the IPO market shows early signs of reopening, with a modest number of offerings completed in 2025, several digital health companies have emerged on Galen Growth's watchlist as potential 2026 IPO candidates.

These companies are actively positioning themselves with experienced leadership teams and strengthened balance sheets to withstand the volatility of the public markets.

While the IPO window remains selective, it appears increasingly open to businesses that demonstrate meaningful scale, credible growth trajectories, and operational readiness for life as a public company. To take advantage of this opportunity, digital health startups must align closely with evolving investor expectations around profitability, discipline, and long-term value creation. Galen Growth expects most IPO activity in the US to occur in the first three quarters of the year, before potential political uncertainty due to mid-term elections.

Included Health MATURITY 95.0 PRIMARY CATEGORY Medical Concierge	Zelis MATURITY 67.5 PRIMARY CATEGORY Medical Payments	Virta Health MATURITY 78.7 PRIMARY CATEGORY Digital Therapeutics
Maven MATURITY 84.1 PRIMARY CATEGORY Teleconsultation	Aledade MATURITY 91.5 PRIMARY CATEGORY Physician / Clinic	Transcarent MATURITY 76.1 PRIMARY CATEGORY Medical Concierge
Doctolib MATURITY 91.0 PRIMARY CATEGORY Medical Concierge	Kindbody MATURITY 70.1 PRIMARY CATEGORY Teleconsultation	Lyra Health MATURITY 89.4 PRIMARY CATEGORY Corporate Health

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2026 Predictions: What Will Matter

After years of bold promises, digital health in 2025 was all about **delivering results**. Funding levelled off to healthy, sustainable levels, and the industry focused on what works rather than on what merely sounds exciting. 2026 is expected to bring **more results and more reality**. Specifically, **AI and interoperability** are expected to deliver on their promises, and **digital tools** will continue to broaden in scope.

Regulation

Consumer & wearable health data becomes clinical-grade



Regulatory frameworks for AI in medicine get clearer



Healthcare Delivery


Embedded AI-driven clinical decision support goes mainstream



Virtual care evolves beyond teleconsultation to healthcare everywhere



Digital therapeutics (DTx) get wider adoption & reimbursement



Personalised medicine will be powered by multi-omics, AI, & lifestyle data



Technology

Health equity becomes a core digital strategy




Healthcare interoperability finally works




Venture Capital

Cybersecurity and patient data trust are priority #1



VC Funding will continue to climb, as the IPO market opens further




© 2026 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Global 2025


Ecosystem Insights 2025:
Fewer Bets, Higher Standards

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Venture Universe: Growth, and Survivorship

The global digital health ecosystem was comprised of 11,379 active, private ventures at the end of 2025 and and has been expanding at a five-year compound. North America remains is the largest regional ecosystem, accounting for 41% of all Digital Health ventures globally.

Global Distribution of Ventures



Cumulative Volume of Private & Active Ventures, 2021 – 2025



Note: venture volume for recent years is expected to increase as ventures emerge from stealth

© 2026 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Partnerships Fell Again: Fewer Pilots, Higher Bars


Partnerships in the digital health sector continued the steady decline that began in Q2 2024, reaching a 5-year low by the end of 2025, with just over 2,370 partnerships recorded. Many industry players are moving away from handfuls of pilots with multiple ventures and focusing on the partners that can deliver results across the business.

Health Management Solutions and Medical Diagnostics remained the most active areas for partnerships in 2025, suggesting a focus on leveraging AI technologies and expertise to enhance diagnostic capabilities and improve health systems' infrastructure tools.

Growth of Partnerships in Digital Health by Quarter and Region



2025 Venture Partnership Distribution by Digital Health Cluster



© 2026 by Galen Growth - All rights reserved.

Partnership Decline Implications

IMPLICATIONS

Investors		Partnership volume is not a growth proxy; **focus on partnership quality—depth, revenue attachment, renewal rates, and operational integration**; beware “announce-and-move-on” deals.
Corporates		**Treat partnerships as scarce resources**—standardise evaluation and demand concrete deliverables (integration milestones, adoption targets, evidence generation, commercialisation plan).
Health Systems		Integration fatigue is real—**prioritise vendors that reduce complexity**; require interoperable design, minimal workflow disruption, and clear ownership of implementation work.
Ventures		Expect fewer “logo partnerships” and more scrutiny; win by making integration easy, demonstrating early value, and offering a credible scale plan (not a press release plan).

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Evidence is the Price of Entry


While the number of regulatory filings and peer-reviewed publications increased in 2025, clinical trials decreased – likely due to ventures focusing on the evidence needed and avoiding high-cost trials.

Looking at the distribution by cluster, Medical Diagnostics accounted for 25% of ventures with an Evidence Signal (ES) greater than 40, indicating that these ventures have run clinical trials, filed regulatory applications, or published at least 4 peer-reviewed papers. Across the top-funded therapeutic areas, ventures in Cardiovascular Diseases and Neurology took the top spots.


Ventures founded in Europe led the globe in the share of ventures with an Evidence Signal > 40.

Global Region	# of Ventures with Regulatory Filings in 2025	% Ventures with Evidence Signal > 40
North America	386	26%
APAC	366	22%
Europe	354	32%
Middle East	31	28%
South America	1	10%
Africa	11	10%


Growth of Evidence for Clinical Strength



Share of Ventures in Top 6 Therapeutic Areas (by 2025 Funding Value) with Evidence Signal > 40



Share of Ventures with Evidence Signal > 40 by Primary Digital Health Cluster



© 2026 by Galen Growth - All rights reserved.

Clinical Evidence Implications

Investors		Evidence is now a valuation driver and a risk reducer; diligence should separate “validation” from “outcomes” and **confirm that evidence is aligned with the buyer’s purchasing criteria**.
Corporates		**Build evidence into partnerships from day one** (study design, endpoints, RWE collection); use outcomes to accelerate internal buy-in and external adoption.
Health Systems		**Make evidence requirements explicit and standardised**; prioritise vendors who can measure impact in your environment and share results transparently.
Ventures		**Treat evidence as a product capability**—instrument outcomes, define clear endpoints, and publish credible results; buyers will increasingly require proof before scaling.

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Product Winners: AI + Workflow, Not AI + Novelty

HealthTech Alpha has catalogued over 56,000 products, including mobile apps, software, devices, and more, developed by digital health ventures. The data reveals that North America and Europe share a similar distribution of product type, predominantly software solutions. However, notable regional differences emerge in Asia Pacific and the Middle East, where digital health ventures demonstrate a significantly higher reliance on mobile applications.

Distribution of Venture Products, by Product Type and Region



Distribution of Product Type for Digital Health Clusters with the Most Products




© 2026 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Global 2025


Investment Insights 2025:

Bigger Cheques, Fewer Teams Funded

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Average Deal Size Rose: Conviction Concentrated

After 2 years of hesitating to make high-value investments, investors are now seeing openings in the IPO market and seizing the moment to fund growth- and late-stage ventures with an eye on increasing the number of exits in 2026 and 2027. Across the globe, quarterly funding deals in digital health have reached a 5-year low, with only 277 deals in Q4. However, average deal size is on the rise, up 2.2x year-over-year to a 5-year high of $34.1 million in Q4.




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Where the Money Went in 2025 (by Region)

Region	Total Funding (% change from FY 2024)
North America	$19.5B ▲ (7%)
Europe	$6.2B ▲ (15%)
Asia Pacific	$2.4B ▲(14%)
Middle East	$572M ▲ (11%)
South America	$72M ○ (-3%)
Africa	$20M ▼ (-54%)




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

High-Value Deals Increase the Average Deal Sizes

With deal sizes increasing across all funding stages, early- and late-stage deals saw the most significant jump, each up 1.6x from 2024. Across the digital health ecosystem, the global average deal size increased across all funding rounds, showing a positive trend for ventures experiencing funding stress.

Global Average Deal Size by Funding Year and Stage




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Strong Finish: Year-End Confidence Improved

Global digital health funding ended 2025 on a strong note, with quarterly investments increasing from Q3 to Q4 in Europe, Asia Pacific and North America, the three highest-funded regions.



© 2026 by Galen Growth - All rights reserved.


FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Funding is Up Across Early, Growth and Late Stages


For the second consecutive year, funding rose in four of the five categories, led by a 19% increase in Series B rounds and a 16% rise in Series D and later-stage rounds compared with 2024.

The US and Europe have continued their dominance in funding, capturing 83% of the global venture capital funding deals in 2025 and 89% of the funding value.

Venture Funding Value by Funding Stage












Share of Investment Volume (2021 – 2025)



© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED










Digital Health Funding Across Regions, 2021-2025

	North America	Asia Pacific	Europe
Cumulative Venture Capital Investment 2021 – 2025	$117.2B	$23.5B	$30.1B
Funding by Year, 2021 –2025			
Cumulative Venture Capital Deal Volume 2021 – 2025	5728 Deals	1719 Deals	3219 Deals
Deal Volume by Year, 2021 – 2025			
Average Deal Size, 2021 – 2025			

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Digital Health Funding Across Regions, 2021-2025

	Middle East	South America	Africa
Cumulative Venture Capital Investment 2021 – 2025	$3.9B	$977M	$362M
Funding by Year, 2021 –2025			
Cumulative Venture Capital Deal Volume 2021 – 2025	280 Deals	94 Deals	131 Deals
Deal Volume by Year, 2021 – 2025			
Average Deal Size, 2021 – 2025			

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Runway Signal: Ecosystem Capital-stress?

Global Funding Strength remains at critically low levels for many Digital Health ventures that have not raised funding in 18 months, the typical runway period for a raise.


With global averages revealing only 23% of Early Stage ventures, 31% of Growth Stage ventures, and 47% of Late Stage ventures have raised funds in the last 18 months, the remainder of the ecosystem is vulnerable to cash shortages.

The average number of months that have elapsed since the last raise for Growth Stage ventures is nearly 15 months higher for ventures in Asia Pacific than those in Europe and the US.

Funding Strength: average number of months that have elapsed since the last funding round for the Growth Stage ventures



Global average percentage of ventures that have raised funding, by funding interval and current funding stage



© 2026 by Galen Growth - All rights reserved.

Funding Strengths Implications

Investors		Distress risk is rising beneath headline funding—expect down-rounds, recapitalisations, and distressed M&A; **diligence should stress-test cash burn, gross margin, and renewal resilience**.
Corporates		Venture solvency becomes a procurement variable—**include financial viability checks, step-in rights, and data escrow clauses for critical suppliers**.
Health Systems		Reduce venture risk exposure—**avoid mission-critical dependencies on undercapitalised suppliers**; plan for continuity (data portability, transition pathways).
Ventures		Assume fundraising is not guaranteed: move to “default alive” planning, reduce burn, deepen retention, and prioritise revenue that is repeatable and **contractable.**

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Investor Participation: Few Active Investors, Higher Influence

Globally, more than 15,000 investors have participated in at least one Digital Health funding deal in the past 15 years. Since 2020, nearly 4,400 investors have participated in at least 2 funding deals, while 574 have participated in 10 or more.

Global Analysis of Digital Health Investors (all-time)



5-Year Global Deal Participation (2021 – 2025)
Number of unique investors* by cumulative investment count



* Accelerator and grant programs have been excluded


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Investor Base Contraction: Fewer Active Investors Matter More


The count of investors that have participated in at least one deal in digital health in a calendar year reached 3,968 investors in 2021, but 2023 and 2024 saw many investors turning their backs on the sector, with 2025 showing a decrease in investor count of 38% from 2021, leaving only 2472 investors participating in 1335 deals. Of the over 10,000 investors from 2021 to 2025, only 3.6% have participated in rounds in each of the past 5 years.

Count of Investor Participation by Year



Recurring Investor Participation (2023 – 2025)

Overlap indicates investors participating in multiple time periods




543 investors participated in each of the three years from 2023 - 2025

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Overview: Global Distribution of Investment Activity in 2025

Number / share of investors that participated in deals for ventures founded in the regions & countries shown. Investors can be active in multiple regions.



Number of Investors, by Country of Investment

> 1000

0

Regional share of active investors (will not add to zero, since investors can be active in more than one region)

North America

1504
Active Investors

$19.5B
Funding Deployed in 2025

Europe

721
Active Investors

$6.2B
Funding Deployed in 2025

Asia Pacific

443
Active Investors

$2.4 B
Funding Deployed in 2025

South America

32
Active Investors

$72M
Funding Deployed in 2025

Africa

9
Active Investors

$20M
Funding Deployed in 2025

Middle East

94
Active Investors

$572M
Funding Deployed in 2025

Global Summary, 2025

16,100 Ventures

2,472 Active Investors in 2025

$28.8B Funding Deployed in 2025

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Global Digital Health Investor Participation in 2025

General Catalyst, Andreessen Horowitz and the Gates Foundation top the list as the most prolific investors in 2025 (not including accelerators and government grant programs), cumulatively participating in more than 75 digital health deals. See Galen Growth's HealthTech 50 Core Investors 2025 report for a deeper look at Digital Health investors.

Global Top 5 most active VC investors in 2025

Investor	Type	# of Digital Health Deals in 2025	# of Digital Health Investments since 2010	Recently Participated Investment	Date	Deal Value
General Catalyst	Venture Capital	36	218	Chai Discovery	12 / 2025	$130M
Andreessen Horowitz	Venture Capital	20	169	Function Health	11 / 2025	$298M
Gates Foundation	Venture Capital	19	231	EMGuidance	11 / 2025	$914k
Khosla Ventures	Venture Capital	17	201	Faeth Therapeutics	10 / 2025	$25M
Alumni Ventures	Venture Capital	17	79	Emm	11 / 2025	$9M

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Alpha Forecaster™
Faeth Therapeutics is a clear choice

Faeth Therapeutics

COUNTRY OF ORIGIN
United States

PRIMARY CATEGORY
Disease Management

LATEST FUNDING
$25M (Series B)

THERAPEUTIC AREA
Oncology, Nutrition


INC. DATE
12 / 2019

MATURITY SCORE
62.5

DESCRIPTION

Faeth is a data-driven, evidence-based company with a deep mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. We are fully focused on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy, and we're in clinical trials now.

Venture Scores and Analysis



	Venture Score	Peers Average
Alpha Score	62.6	51.9
Momentum Index	63.3	49.7
Market Index	60.9	57.0
Money Index	47.0	28.5
Innovation Index	38.1	35.1
Team Signal	53.3	54.6
Evidence Signal	58.4	42.7
Partnership Signal	0.0	46.3


Full Profile in HealthTech Alpha

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Global 2025

Cluster Focus 2025:

Workflow-Adjacent Categories Outperformed

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Galen Growth's Digital Health Taxonomy™ – the industry standard

Health Management Solutions
- EHR / PHR
- Hospital
- Pharmacy
- Physician / Clinic
- Prescriptive Analytics

Health Services Search
- Healthcare Navigation
- Medical Concierge
- Medical Tourism
- Triage

Health InsurTech
- Health Claim Management
- Health Insurance
- Medical Payments

Medical Diagnostics
- Diagnosis Tools
- Medical Imaging
- Omics Related Diagnosis

Medical Education
- Consumer Education
- HCP Education
- Health Information Platform

Online Health Communities
- Other HCP Networks
- Patient Health Forums
- Physician Networks

Online Marketplace
- Consumer Marketplace
- On-demand Lab Tests
- Online Pharmacy
- Professional Marketplace

Patient Solutions
- Digital Therapeutics
- Disease Management
- Health / Symptom Checker
- Medication Management

Population Health Management
- Care Coordination
- Corporate Health
- Home Healthcare
- Integrated Solutions

Remote Devices
- Assistive Care
- Remote Diagnostic Devices
- Remote Monitoring Devices

Research Solutions
- Bioinformatics
- Drug Discovery
- Omics Related Research

Clinical Trials
- Decentralized Clinical Trials
- Clinical Trial Matching
- Data Collection Tools
- Clinical Trial Design

Telemedicine
- Teleconsultation
- Telepathology
- Teleradiology
- Telesurgery

Veterinarian
- Animal Health Forums
- Animal Imaging
- Animal Monitoring
- Omics Related Veterinary
- Televeterinary

Wellness
- Omics Related Applications
- Smart Equipment
- Wearables
- Wellness Apps
- Wellness Information Platform

Safety & Security
- Counterfeit Tracking
- Cybersecurity
- Pharmacovigilance

Healthcare Logistics
- Transportation Management
- On-demand Delivery

Others
- Contamination Management
- HCP Job Board
- Healthcare Marketing
- Social Enterprise
- Software Provider

Digital Health / HealthTech Cluster

Category


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Funding by Cluster: the 2025 Leaderboard

Health Management Solutions moved into the top spot for Digital Health funding in 2025, with 51% of the $5.45 billion raised originating in 14 mega deals by ventures in the cluster, including $300 million deployed in June for medical notetaking venture Abridge. With $4.49 billion of venture capital deployed over 144 deals, Research Solutions took the second-place spot.

2025 Top Funded Digital Health Clusters




	Digital Health Cluster	Total Funding Globally in 2025	Rank in 2024	Largest Deal in 2025
1	Health Management Solutions	$5.45B	#3	Abridge $300M (Series E)
2	Research Solutions	$4.49B	#1	Isomorphic Labs $600M (Strategic)
3	Medical Diagnostics	$2.62B	#2	Neko Health $260M (Series B)
4	Telemedicine	$2.53B	#6	Hims & Hers $1.0B (Convertible Note)
5	Wellness	$2.34B	#8	Oura $900M (Series E)

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Health Management Solutions Pushes TechBio into Second Place

Research Solutions appears to have reached the peak of funding in 2024, while Health Management Solutions, which includes tools for clinical and non-clinical workflow, EHR, and AI solutions for clinical notetaking, has surged in uptake by health systems and took the top spot in 2025 for total funding deployed.




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2025 Top 10 Digital Health Clusters by Venture Funding Value

With $5.5 billion of venture funding deployed over 209 deals in 2025, Health Management Solutions has secured the most funding worldwide, while it also is the largest cluster by global number of ventures. Medical Diagnostics, being the second-largest cluster, has garnered nearly the same investment volume (208 deals), yet with $2.6 billion it stands third in the overall venture capital rankings.



Note: The chart above shows venture funding and volume according to venture primary cluster

© 2026 by Galen Growth - All rights reserved.

Cluster Focus Implications

Investors		The winning clusters share the same traits: workflow adjacency, buyer ROI clarity, and lower evidence friction; **build theses around adoption mechanics, not hype cycles**.
Corporates		Cluster leaders can be leveraged as distribution partners (provider channels, operational workflows); **prioritise solutions that slot into care pathways and generate measurable outcomes.**
Health Systems		Use cluster signals to guide procurement strategy—**prioritise categories that demonstrably relieve capacity constraints and reduce clinician admin burden.**
Ventures		**Choose a wedge that maps to a real buyer pain point**; win adoption first, then expand; evidence strategy should be proportionate and designed to unlock procurement at scale.

IMPLICATIONS

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Alpha Forecaster™
Abridge soars above its peers

ABRIDGE

Abridge

COUNTRY OF ORIGIN
United States

PRIMARY CATEGORY
Physician / Clinic

LATEST FUNDING
$300M (Series E)

THERAPEUTIC AREA
Disease Agnostic


INC. DATE
02 / 2018

MATURITY SCORE
84.0

DESCRIPTION

Abridge provides an enterprise-grade generative AI platform that transforms patient-clinician conversations into contextually aware, clinically useful, and billable medical notes in real time. Its technology reduces clinicians' cognitive load, improves documentation efficiency, and integrates deeply with major EHR systems. Health systems use Abridge to support clinicians, nurses, and revenue-cycle teams with accurate, compliant, and auditable AI-generated documentation

Venture Scores and Analysis



	Venture Score	Peers Average
Alpha Score	84.0	66.3
Momentum Index	67.3	53.0
Market Index	79.1	64.2
Money Index	86.8	52.3
Innovation Index	66.7	62.1
Team Signal	81.4	58.6
Evidence Signal	67.3	43.8
Partnership Signal	86.9	62.8


Full Profile in HealthTech Alpha

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Global 2025

Therapeutic Focus in 2025:


Concentration Mirrors Clinical & Commercial Gravity

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2025 Venture Funding in Key Therapeutic Areas

In 2025, ventures offering Disease Agnostic solutions raised half (50%) of the funding deployed across the globe. Oncology maintained the top therapeutic area spot with $3.6 billion of venture capital deployed, while Women's Health jumped into the second-place spot with $2.7 billion.

Top Funded Therapeutic Areas in 2025



Therapeutic Areas		Total Funding Globally, 2025	Rank in 2024	Largest Deal in 2025
1	Oncology	$3.6B	#1	Transcarent $481M (Private Equity)
2	Women's Health	$2.7B	#3	Hims & Hers $1.0B (Convertible Note)
3	Mental Health	$2.3B	#2	Harbor Health $130M (Series B1)
4	Preventive Health	$1.9B	#10	Oura $900M (Series E)
5	Neurology	$1.7B	#4	Synchron $200M (Series D)


Note: ventures can have solutions across multiple therapeutic areas. Funding is counted in all applicable areas.

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Top 10 Therapeutic Areas by Venture Funding Value, 2021 –2025

Oncology retains the top spot in 2025, despite a 12% decrease of venture capital invested YoY. Women's Health saw a 10% gain in funding over 2025, while investment in ventures with solutions in Preventive Health increased by 104%.




© 2026 by Galen Growth - All rights reserved.

Note: ventures can have solutions across multiple therapeutic areas. Funding is counted in all applicable areas.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Depth vs. Dollars: Where Crowded TAs Still Attract Capital

The top five largest therapeutic areas (by number of active, private ventures) captured the highest number of deals and took the top 5 spots for venture funding value in 2025. While Oncology has remained the top-funded therapeutic area over the past 5 years, Mental Health, the largest cluster, saw a 18% decrease of venture capital funding deployed YoY, to reach $2.3 billion in 2025 and fell behind the $2.7 billion deployed in Women's Health.



Note: ventures can have solutions across multiple therapeutic areas. Funding is counted in all applicable areas.

© 2026 by Galen Growth - All rights reserved.

Therapeutic Focus Implications

Investors		Therapeutic ‘heat’ reflects reimbursement clarity, evidence demands, and route-to-market. **Diligence should focus on endpoint feasibility, adoption drivers, retention and margin trends, and concentration of capital**.
Corporates		**Prioritise fewer, deeper partnerships in therapeutic areas where digital can improve outcomes with measurable value**. Anchor BD on scalability and evidence aligned to payer/ provider decisions, not pilots.
Health Systems		Therapeutic trends guide service-line priorities; **demand interoperability, rollout ownership, and outcomes that hold locally**. In crowded areas, favour consolidation and stack simplification over new point solutions.
Ventures		Therapeutic appeal alone isn’t enough—procurement demands evidence, integration readiness, and real differentiation; **in crowded categories, structural differentiation is mandatory**.

IMPLICATIONS

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Alpha Forecaster™
Ōura Signals Future Success

ŌURA

Oura

COUNTRY OF ORIGIN
Finland

PRIMARY CATEGORY
Wearables

LATEST FUNDING
$900M (Series E)

THERAPEUTIC AREA
Preventive Health, Sleep


INC. DATE
01 / 2013

MATURITY SCORE
93.8

DESCRIPTION

Oura is a digital health company that builds a sleep and wellness optimization platform centered around the Oura Ring and its companion app. The company helps consumers better understand their bodies by providing daily, personalized insights on sleep quality, recovery, and overall health.

Venture Scores and Analysis



	Venture Score	Peers Average
Alpha Score	93.8	50.0
Momentum Index	72.6	47.6
Market Index	92.6	49.8
Money Index	89.5	28.5
Innovation Index	92.9	40.2
Team Signal	75.1	53.2
Evidence Signal	62.2	49.0
Partnership Signal	92.4	54.8

Full Profile in HealthTech Alpha

Global 2025

Regional Snapshots 2025:

Different Buyers, Constraints & Winners

North America

Europe


Asia Pacific

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Snapshot

United States:

Scale, Late Stage Depth & Provider-Led Demand

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

2025 Snapshot: United States


North America 2025 Funding Distribution

Funding by Country

Country	2025 Total Funding
United States	$19.2B ▲
Canada	$225M ▲
Mexico	$38M ▼

Top 10 US States by Funding Value

State	2025 Total Funding
California	$6.63B ▼
New York	$3.23B ▼
Massachusetts	$1.70B -
Texas	$1.30B ▲
Pennsylvania	$879M ▲
Colorado	$810M ▲
Illinois	$600M ▼
Maryland	$516M ▲
New Jersey	$415M ▲
Washington	$388M ▼



Note: Percentages represent funding as a fraction of total funding in prioritized North America countries only (United States, Canada, Mexico)

© 2026 by Galen Growth - All rights reserved.

US Snapshot Implications

Investors		Provider adoption is now the clearest indicator of staying power. **Understanding why certain therapeutic areas consistently lead will help you interpret where durability and value are most likely to emerge.**
Corporates		Big Tech now anchors the U.S. digital health stack; align strategy to their cloud, data, and AI ecosystems. **Build modular, interoperable tech that plugs directly into dominant platforms to accelerate adoption and scale.**
Health Systems		Providers set the pace of innovation in the U.S.—use this leverage to **demand interoperability, rapid implementation, and ROI-linked proof from every vendor**.
Ventures		For health system adoption, fast integration, clear ROI, and tangible workflow impact are non-negotiable. **Stay flexible and adapt quickly to shifting US regulations**, as speed can help you stand out in a crowded market.

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Investment Focuses on Health Management Solutions

The U.S. maintained its dominant position in the global digital health funding arena during 2025, attracting $19.2 billion across more than 700 deals, up 7% YoY. Oncology took the top spot in North America, despite a 14% decrease year-on-year in venture funding value. Investment in ventures focused on Health Management Solutions increased 70% YoY to become the top-funded Digital Health cluster.

Change in Venture Funding for the Top 5 Therapeutic Areas (by funding value)



2025 Top Funded Digital Health Clusters




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


US Adoption: Providers are the Primary Adoption Engine

Health systems continue to increase their adoption of digital solutions, reflected in the fact that 19% of U.S. digital health partnerships announced involved health systems and U.S.-based ventures. At the same time, the number of partnerships declined sharply globally, a trend also evident among U.S. ventures. Despite this contraction, U.S. ventures announced a proportionally higher number of partnerships in Q4, driving a notable increase in the U.S. share of global partnerships. This shift suggests a market that is consolidating around fewer, more mature vendors, with health systems and others prioritizing proven solutions and deeper strategic relationships over broad experimentation.

Share of Partnerships by Industry Vertical



Growth of Partnerships in the US by Quarter and Share of Global Partnerships



© 2026 by Galen Growth - All rights reserved.

Snapshot

Europe:


Momentum & Cross Border Capital, with Valuation Sensitivity

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Europe 2025 Funding Distribution

Top 10 Countries in Europe by Funding Value

Country	2025 Total Funding
United Kingdom	$2.11B ▲
Finland	$1.16B ▲
France	$731M ▼
Germany	$612M ▼
Sweden	$418M ▲
Switzerland	$381M ▼
Spain	$211M ▼
Belgium	$104M ▼
Poland	$73M ▲
Iceland	$68M ▲



Note: Percentages represent venture funding as a fraction of total funding in European Key Markets

© 2026 by Galen Growth - All rights reserved.

Europe Snapshot Implications

Investors		U.S. capital is lifting European valuations—stay grounded in what the market can actually support. **Focus on understanding evidence strength and local adoption dynamics** to gauge real durability.
Corporates		Pharma influence remains strong, creating a stable environment for clinically rigorous digital partnerships. Europe's steadier regulatory climate lets you **plan long-term tech strategies** without constant recalibration.
Health Systems		Europe's evidence-first culture gives you leverage to demand high-proof, low-hype solutions. Use regulatory stability to **scale technologies that demonstrate real clinical or operational value**.
Ventures		**Stay focused on evidence and local fit rather than chasing U.S.-driven valuation pressure**. Strong clinical validation and alignment with target buyers will set you apart in a more disciplined, proof-driven ecosystem.

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Venture Funding Focuses on Oncology and TechBio in 2025

With strong first and fourth quarters, Europe's Digital Health sector manifested its position as the second most funded region in the world with $6.2 billion across 550 deals. Aligned with the global trend, Preventive Health took the top therapeutic area spot in Europe, driven by the fourth quarter $900 million Series E investment in Ōura. Wellness and Research Solutions pushed ahead of Medical Diagnostics as the top-funded Digital Health clusters in Europe.

Change in Venture Funding for the Top 5 Therapeutic Areas (by funding value)



2025 Top Funded Digital Health Clusters




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Venture-to-Venture Partnerships Surge in 2025

Partnerships involving European ventures collapsed over 2025, with only 26 partnerships announced in Q4. but declined in the latter half, culminating in 328 partnership announcements for the year. Venture-to-venture collaborations accounted for 28% of these announcements, while Healthcare Providers (including health systems) and Pharma companies represented 20% and 15% of the partnerships, respectively.

Share of Partnerships by Industry Vertical



Growth of Partnerships in Europe by Quarter and Share of Global Partnerships



© 2026 by Galen Growth - All rights reserved.

Snapshot

Asia Pacific:


Selective Capital with Strong Diagnostic & Oncology Pulls

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Asia Pacific 2025 Funding Distribution

Top 10 Countries in Asia Pacific by Funding Value

Country	2025 Total Funding
Australia	$548M ▲
China	$520M ▲
India	$416M ▼
Hong Kong	$393M ▲
Japan	$255M ▼
South Korea	$142M ▼
Singapore	$95M ▲
New Zealand	$26M ▲
Taiwan	$21M ▲
Pakistan	$6M ▲



© 2026 by Galen Growth - All rights reserved.

Asia Pacific Snapshot Implications

Investors		APAC capital is selective—durability depends on understanding each market's regulatory and commercial realities. **Local fit often beats global scale, so read signals through country-specific contexts**.
Corporates		Pharma remains influential, making clinically aligned digital partnerships effective across APAC. **Success requires country-tailored strategies that adapt to diverse reimbursement, data, and adoption environments**.
Health Systems		APAC systems prioritize solutions that strengthen diagnostics, oncology, and operational capacity. **Choose partners who can localize quickly and operate reliably** within your regulatory and workflow constraints.
Ventures		Winning in APAC demands tight alignment to local clinical needs and the agility to adjust pricing, workflow, and go-to-market by country. **Local credibility and trusted partnerships matter more than global branding**.

IMPLICATIONS


© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


APAC Funding Focus: Women's Health & TechBio Gained Attention

Asia Pacific's Digital Health sector increased in venture funding over 2025, attracting a total of $2.4 billion across 187 deals, up 14% from $2.1 billion in 2024. Ventures focused on Women's Health and Oncology took the top therapeutic area spots for venture capital deployed. Australia emerged as the top country, with $548 million of funding deployed.

Change in venture funding for the top 5 Therapeutic Areas (by funding value)



2025 Top Funded Digital Health Clusters




© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


APAC Partnerships Broadly Distributed Across Industry Verticals

Digital Health partnerships across Asia Pacific are broadly spread across industry verticals. Whereas only venture-to-venture and health systems collaborations have accumulated 48% of the partnerships in Europe, nearly the same share of partnerships is spread over 4 industry verticals in APAC. Although APAC ventures increased their share of global partnerships across the second and third quarters of 2025, partnerships in the fourth quarter fell sharply.

Share of Partnerships by Industry Vertical



Growth of Partnerships in Asia Pacific by Quarter and Share of Global Partnerships




© 2026 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



Reference Notes

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

Key Information & Data Notes

Scope of Report

This report covers Digital Health ventures with incorporation date after 2002. The data is valid as of 02 Jan 2026.

Digital Health is defined as the intersection between healthcare and technology, and is also referred to as HealthTech. Digital Health does not include Biotech (protein research or pharmaceuticals), MedDev (devices that are mechanical and electronic in nature), neuro-stimulates, opioids and minimal-invasive instruments.
We recommend reviewing our taxonomy on the next page for further details.

Data Sourcing and Tracking

Galen Growth tracks a comprehensive inventory of key data points ranging from company demographics, funding and valuation to in-market capabilities on a continuously growing and curated list of HealthTech ventures drawn from global markets. Data is collated from primary research, public domain sources (press releases, news, public fillings), proprietary analytics and from its unique network.

The information is:

- Disclosed and undisclosed by nature
- Continuously updated with the latest data
- Curated from both direct and indirect verified sources
- Augmented with our proprietary algorithms

Each HealthTech Alpha Index and Score is calculated using proprietary algorithms and data points drawn from our carefully curated HealthTech Alpha database. We recommend reviewing the Alpha Forecaster™ Analytics section for further insights.

Key Terms and Definitions

BASE CURRENCY	USD
EARLY STAGE	All deals up to Series A stage
GROWTH STAGE	All deals at Series B & C stage
LATE STAGE	All deals at Series D & Beyond stage
EXIT	IPO, SPAC and M&A deals
HTA	HealthTech Alpha

Important Information

This report is provided solely for informational purposes and was prepared in good faith on the basis of public information available at the time of publication without independent verification. Numbers will be updated from to time to reflect information identified after the event.

Galen Growth does not guarantee or warrant the reliability or completeness of the data nor its usefulness in achieving any particular purposes.


Galen Growth shall not be liable for any loss, damage, cost or expense incurred by any reason because of any person's use or reliance on this report.

This report is a proprietary aggregation of publicly available and undisclosed data and shall not be forwarded or reproduced without the prior written consent of Galen Growth.

Research Inquiries

For more information about data, research and Galen Growth's proprietary algorithm contact: research@galengrowth.com for more information.

© 2026 by Galen Growth - All rights reserved.



10 YEARS GALEN GROWTH
A Decade of Redefining Digital Health Intelligence


Digital Health Clusters and Categories

With 66 Digital Health categories across 18 clusters, Galen Growth's comprehensive taxonomy streamlines venture discovery and analysis.

Health Management Solutions	Health Services Search	Health InsurTech
Medical Diagnostics	Medical Education	Online Health Communities
Online Marketplace	Patient Solutions	Population Health Management
Remote Devices	Research Solutions	Clinical Trials
Telemedicine	Veterinarian	Wellness
Safety & Security	Healthcare Logistics	Others

Mapping across the value chain

Further classification of target users and value propositions




© 2026 by Galen Growth - All rights reserved.

Alpha Forecaster™ Analytics

The Alpha Score is a 360° Venture Maturity assessment that aggregates four distinct and independent Alpha Indices

- Momentum index: evaluates the present performance and fitness of the venture relative to its ecosystem peers.
- Money index: quantifies the financial strength and wellbeing of the venture based on its financial history and investor quality.
- Market index: evaluates the health of the sector category and sub-category in which a startup competes
- Innovation index: evaluates the degree to which the venture is solving healthcare pain points



The Team Signal evaluates the strength of the venture's leadership team.

The Partnership Signal evaluates the strength of the venture's partnership network.

The Venture Similarity Score indicates the commonality of existing data points between startups within the HealthTech Alpha database.

The Venture Valuation estimates the current and next funding stage valuation of a venture based on mark-to-market calibration.

The Evidence Signal is an indicator of the amount of evidence that a venture has accumulated to confirm the benefit of its solution to the target customer.


© 2026 by Galen Growth - All rights reserved.

HEALTHTECH ALPHA

Request your free trial of HealthTech Alpha today

Better-informed Digital Health innovation choices are just a click away with **HealthTech Alpha, the AI-native platform for Digital Health market intelligence and benchmarking**. Our comprehensive specialist data gives you all the information you need to make winning decisions.

Get started



About Galen Growth

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

The Company Behind HealthTech Alpha

Unrivalled Intelligence for a Competitive Edge:

- Actionable Market insights
- Data-Driven Decisions
- Unmatched Ecosystem Visibility

Talk to us

Deep Digital Health Ecosystem Coverage

Through HealthTech Alpha, we deliver unmatched coverage depth and breadth across the world's most innovative Digital Health ventures.



Specialist Team with Decades of Experience

Our specialist team designs, maintains, and evolves HealthTech Alpha's data, models, and analytical frameworks, ensuring continuous accuracy and relevance.

Our US, Asia and Europe offices serve our clients worldwide.

Proven Innovation Solutions

Whatever stage you are at in your innovation journey, we have a best-in-class solution to enable you to succeed. Every solution leverages our unrivalled Digital Health data.

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED



HealthTech Alpha

The most trusted Digital Health actionable intelligence and insights platform for healthcare leaders

HealthTech Alpha is the AI-native foundation of our work, combining proprietary Digital Health datasets, structured taxonomies, and advanced analytics to function as a system of record for the ecosystem.

Whether you are determining a market entry strategy, fine-tuning Digital Health product development, looking to benchmark and differentiate against your competition or researching future Digital Health innovation, HealthTech Alpha has you covered.

Get started with HealthTech Alpha and make better data-driven innovation decisions.

Learn more:

Find Best-Fit Ventures | Due Diligence | Ecosystem Insights | Competitive Intelligence

Request Free Trial

© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED


Alpha CoPilot - Your AI-Powered Research Assistant

Grounded exclusively in HealthTech Alpha's proprietary data and taxonomy — no generic web scraping, no hallucinations.

Unlock insights hidden deep within HealthTech Alpha.

Delivers fast, expert-level insights using our proprietary data – no noise, no hallucinations.

Request Free Trial



© 2026 by Galen Growth - All rights reserved.

FOR THE USE OF THE PURCHASER ONLY | RESALE AND DISTRIBUTION PROHIBITED

The Industry Go-to-Reference for Digital Health Research

We leverage HealthTech Alpha's platform intelligence and proprietary datasets, complemented by in-house domain experts, to publish thematic research on the Digital Health ecosystem

- Is Big Tech Important to Digital Health Innovation?
- Q2 2025 Digital Health Funding: From Hype to Health Impact
- Clearing the Bottleneck: How Digital Innovation is Driving Clinical Trials
- Digital Health Innovation in U.S. Health Systems
- Pharmaceutical Digital Health Innovation Index



© 2026 by Galen Growth - All rights reserved.

Let’s Discuss How We Can Deliver Your Digital Healthcare Technology Goals

Galen Growth Inc
United States

Galen Growth Asia Pte Ltd
Singapore

Galen Growth GmbH
Switzerland

Contact Us

Galen Growth USA

+1 (205) 595 9838

brandon.prado@galengrowth.com



Brandon Prado

Brandon leads Galen Growth in North America, bringing over 15 years of experience with leading Data & Analytics providers.

Galen Growth Europe

+41 79 610 1764

julien.desalaberry@galengrowth.com



Julien de Salaberry

Julien is the CEO and leads Galen Growth in Europe, leveraging over 30 years of experience in healthcare.

Galen Growth Asia

+65 8374 8584

dario.heymann@galengrowth.com



Dario Heymann

Dario is the Chief Data & Technology Officer and leads Galen Growth in Asia Pacific.